Geron Corporation – Product Pipeline Review – H2
2011
Reference Code: GMDHC01538CDB
Publication Date: OCT 2011
Geron Corporation – Product Pipeline Review – H2 2011 GMDHC01538CDB / Published OCT 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Geron Corporation – Product Pipeline Review
Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
List of Tables...................................................................................................................................................................................................... 7
List of Figures .................................................................................................................................................................................................... 8
Geron Corporation Snapshot .................................................................................................................................................................................... 9
Geron Corporation Overview .............................................................................................................................................................................. 9
Key Information .................................................................................................................................................................................................. 9
Key Facts ........................................................................................................................................................................................................... 9
Geron Corporation – Research and Development Overview ....................................................................................................................................10
Key Therapeutic Areas ......................................................................................................................................................................................10
Geron Corporation – Pipeline Review ......................................................................................................................................................................13
Pipeline Products by Stage of Development ......................................................................................................................................................13
Pipeline Products – Monotherapy .....................................................................................................................................................................14
Pipeline Products – Combination Treatment Modalities .....................................................................................................................................15
Geron Corporation – Pipeline Products Glance .......................................................................................................................................................16
Geron Corporation Clinical Stage Pipeline Products..........................................................................................................................................16
Phase II Products/Combination Treatment Modalities .................................................................................................................................16
Phase I Products/Combination Treatment Modalities ..................................................................................................................................17
Geron Corporation–Early Stage Pipeline Products ............................................................................................................................................18
Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................18
Discovery Products/Combination Treatment Modalities ..............................................................................................................................19
Geron Corporation – Drug Profiles ..........................................................................................................................................................................20
GRN1005 ..........................................................................................................................................................................................................20
Product Description ....................................................................................................................................................................................20
Mechanism of Action...................................................................................................................................................................................20
R&D Progress .............................................................................................................................................................................................20
GRN163L + Paclitaxel + Carboplatin .................................................................................................................................................................22
Product Description ....................................................................................................................................................................................22
Mechanism of Action...................................................................................................................................................................................22
R&D Progress .............................................................................................................................................................................................22
GRN510 ............................................................................................................................................................................................................24
Product Description ....................................................................................................................................................................................24
Mechanism of Action...................................................................................................................................................................................24
R&D Progress .............................................................................................................................................................................................24
GRNCHND1......................................................................................................................................................................................................25
Product Description ....................................................................................................................................................................................25
Mechanism of Action...................................................................................................................................................................................25
R&D Progress .............................................................................................................................................................................................25
GRNCM1 ..........................................................................................................................................................................................................26
Product Description ....................................................................................................................................................................................26
Mechanism of Action...................................................................................................................................................................................26
R&D Progress .............................................................................................................................................................................................26
GRNIC1 ............................................................................................................................................................................................................27
Product Description ....................................................................................................................................................................................27
Mechanism of Action...................................................................................................................................................................................27
R&D Progress .............................................................................................................................................................................................27
GRNOPC1 ........................................................................................................................................................................................................28
Geron Corporation – Product Pipeline Review – H2 2011 GMDHC01538CDB / Published OCT 2011
©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(2)
Geron Corporation – Product Pipeline Review
Product Description ....................................................................................................................................................................................28
Mechanism of Action...................................................................................................................................................................................28
R&D Progress .............................................................................................................................................................................................28
GRNVAC1 ........................................................................................................................................................................................................29
Product Description ....................................................................................................................................................................................29
Mechanism of Action...................................................................................................................................................................................29
R&D Progress .............................................................................................................................................................................................29
GRNVAC2 ........................................................................................................................................................................................................30
Product Description ....................................................................................................................................................................................30
Mechanism of Action...................................................................................................................................................................................30
R&D Progress .............................................................................................................................................................................................30
Imetelstat + Paclitaxel + Bevacizumab ..............................................................................................................................................................31
Product Description ....................................................................................................................................................................................31
Mechanism of Action...................................................................................................................................................................................31
R&D Progress .............................................................................................................................................................................................31
Geron Corporation – Pipeline Analysis ....................................................................................................................................................................32
Geron Corporation – Pipeline Products by Therapeutic Class ...........................................................................................................................32
Geron Corporation – Pipeline Products by Route of Administration ...................................................................................................................34
Geron Corporation – Recent Pipeline Updates .......................................................................................................................................................35
Geron Corporation – Company Statement ...............................................................................................................................................................38
Geron Corporation – Locations And Subsidiaries ....................................................................................................................................................41
Head Office ...............................................................................................................................................................................